Premium
New developments in small molecules targeting p53 pathways in anticancer therapy
Author(s) -
Cheok Chit Fang,
Lane David P.
Publication year - 2008
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.20261
Subject(s) - mdm2 , drug discovery , small molecule , regulator , cancer research , chemical library , drug , biology , cancer , sirtuin , pharmacology , gene , bioinformatics , genetics , acetylation
The tumor suppressor p53 is frequently inactivated in a wide variety of cancers and point mutations or deletions of the p53 gene are associated with poor prognosis in cancer. About half of all human tumors carry wildtype p53 but p53 wildtype functions are often suppressed by the overexpression of murine double minute 2 (MDM2), a negative regulator of p53. Restoration of p53 functions in tumor cells, therefore, represents an attractive strategy in combating cancer and has been the focus of intensive anticancer drug discovery. One strategy is to antagonize MDM2 functions and initial success was demonstrated in vitro and in xenograft tumor models using newly discovered small molecule inhibitors and antisense oligonucleotides. The new discovery of a compound targeting SirT1 (a member of the sirtuin family) in a p53‐dependent reporter screen highlighted the importance of another negative regulator of p53 and offers an additional avenue for drug discovery and research on p53‐activating therapeutics. Here, we discuss the developments of p53‐activating small molecules and their potential use in combination therapy with established chemotherapeutics. These small molecules were discovered from chemical library screening using biochemical assays or cellular‐based assays, and/or structure‐based rational drug design strategies. Drug Dev Res 69:289–296, 2008. © 2008 Wiley‐Liss, Inc.